Physician profile
Yang Chen
NPI 1972164440
$6,333.32
in general payments reported to CMS, 2019-2025
25 companies · $2,503 in 2025
The $2,503 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.79 · 2022: $903 · 2023: $1,268 · 2024: $1,627 · 2025: $2,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,398.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,638.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,187.47 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $512.71 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $384.51 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $371.93 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $322.97 | 2024-2025 | Qelbree |
| Neos Therapeutics, LP | $252.62 | 2022-2025 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $252.49 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $205.52 | 2023-2025 | Quviviq, Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $146.23 | 2023-2025 | Trintellix |
| Corium, LLC | $145.10 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $138.76 | 2025 | Cobenfy |
| Braeburn INC. | $122.64 | 2025 | Brixadi |
| Tris Pharma INC | $121.44 | 2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $98.63 | 2023-2025 | Ingrezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $94.71 | 2024-2025 | Rexulti |
| Noven Therapeutics, LLC | $80.82 | 2023-2024 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $57.76 | 2024-2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $47.81 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $36.14 | 2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $27.31 | 2025 | Loreev Xr |
| Noven Pharmaceuticals, INC. | $24.27 | 2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $23.91 | 2025 | Invega Sustenna |
| Collegium Pharmaceutical, INC. | $21.96 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $16.65 | 2025 | Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yang Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.